This year, more than 150,000 people died worldwide from kidney cancer. This video represents just a fraction of the toll that this disease has taken. Please take a moment to honor and remember those that we lost this year.
Seventy-five percent of patients will be diagnosed with localized disease – cancer that is confined to the kidney. For most of these patients, surgery will be curative. Because of that fact, few resources exist to support these patients. The assumption is that they are “cured” and no longer need additional care. They are “lucky.” The problem with this logic is that 20...
Every July, we hold our month long, “No Tie July” fundraising effort to raise money for kidney cancer. But this year is different. This year many of us wish we could wear a tie. Offices and workplaces around the world remain closed. And even once workplaces reopen, many people won’t have jobs to go back to. We know that everyone is struggling in this uncertain environment. If you can make a donati...
April 20, 2020 Today, Exelixis and BMS announced positive results from a Phase 3 trial combining Cabometyx (cabozantinib) with Opdivo (nivolumab) as a first-line treatment in advanced RCC. What does that mean for patients? In trial, the combination of Opdivo+Cabometyx showed superiority in both tumor control and overall survival versus patients who were treated with Sutent (sunitinib) alone. More ...